The reassessment of Leqembi’s safety data follows the agency’s previous recommendation of the drug for use in the EU.
The FDA has approved the sBLA for once every 4 weeks lecanemab-irmb (Leqembi®) intravenous maintenance dosing.
Zacks.com on MSN2d
Biogen Stock Down on Regulatory Update in the EU for Alzheimer's DrugThe EC requests CHMP to reassess new safety data that emerged after the positive opinion recommending the approval of ...
In the latest development, the European Commission has asked the EMA's human medicines committee, the CHMP, to take a look at ...
The Washington University trial comes as part of a larger platform study, which hopes to understand whether the disease can ...
The European Commission has requested its medicines regulator to consider safety information on Eisai and Biogen's ...
Biogen and Eisai said they believe that EC's requests can be addressed with existing information, and that no new safety signals have been identified for Leqembi. The U.S. Food and Drug Administration ...
Novartis issued stronger guidance than Wall Street expected. Elsewhere, Eisai and Biogen’s Alzheimer’s drug will get a closer ...
Biogen Inc. (NASDAQ:BIIB), a leading biopharmaceutical company specializing in neurology and rare diseases, finds itself at a critical juncture as it navigates a complex landscape of opportunities and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback